Tazemetostat

EZH2 inhibitor

Tazemetostat is a potent and selective SAM-competitive inhibitor of the lysine methyltransferase EZH2. Tazemetostat displayed strong antiproliferative effects against SMARCB1-deleted malignant rhabdoid tumor (MRT) cell lines *in vitro*. This antitumor activity was also observed in SMARTCB1 mutant mouse xenografts. It displayed potent antitumor activity in various cancer models including non-Hodgkins lymphoma, pediatric glioma, small-cell carcinoma of the ovary, and synovial sarcomas. Tazemetostat has also been shown to control inflammatory genes by modulating IRF1, IRF8, and STAT1 levels suggesting therapeutic potential for the treatment of neuroinflammatory diseases associated with microglial activation.

Ordering Information


Order Online »

ENZ-CHM495-0025

25mg

Manuals, SDS & CofA

View Online »



Handling & Storage

Use/Stability As indicated on product label or CoA when stored as recommended.

Long Term Storage -20°C

Shipping Ambient Temperature

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-

(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide

Appearance Off-white solid.

CAS 1403254-99-8

Couple Target Histone methyltransferase

Couple Type Inhibitor

Formula $C_{34}H_{44}N_4O_4$

Identity Determined by NMR.

MW 572.75

Purity ≥98% (HPLC)

Solubility Soluble in DMSO (>25 mg/ml).

Last modified: February 27, 2025

